Novartis Sees OTCs As Crucial In Emerging – And Emerged – Global Markets
This article was originally published in The Tan Sheet
Executive Summary
Over-the-counter and generic drugs will benefit "disproportionately" compared with prescription drugs in emerging global markets, according to Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh, PhD